Ovid Therapeutics (OVID) Common Equity (2016 - 2026)

Ovid Therapeutics (OVID) has reported Common Equity for 11 consecutive years, with $209.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 276.22% year-over-year to $209.9 million; the trailing twelve-month figure through Jun 2026 stood at $209.9 million (up 276.22% YoY), and the FY2025 full-year result was $130.7 million, up 91.51% from the prior year.
• Common Equity climbed to $209.9 million in Q2 2026 per OVID's latest filing, from $198.3 million in the prior quarter.
• Across five years, Common Equity topped out at $209.9 million in Q2 2026 and bottomed at $44.7 million in Q3 2025.
• Historically, Common Equity has averaged $112.4 million across 5 years, with a median of $106.0 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Common Equity sank 41.41% in 2025, then surged 276.22% in 2026.
• Over 5 years, Common Equity stood at $132.3 million in 2022, then sank by 33.62% to $87.8 million in 2023, then slipped by 22.29% to $68.2 million in 2024, then soared by 91.51% to $130.7 million in 2025, then soared by 60.64% to $209.9 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $209.9 million, $198.3 million, and $130.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.